A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)

Inclusion Criteria: * Participants aged 10 to 60 years old; * Able to obtain informed consent from the participants themselves and/or their guardians; * The participants themselves and/or their guardians are able to comply with the requirements of the clinical trial protocol. Exclusion Criteria: * Axillary temperature \>37.0°C on the day of vaccination; * History of rabies vaccination or administration of rabies virus passive immunization preparations; * History of bites or scratches (with broken skin) by dogs or other mammals within 1 year before the first vaccination; * Suffering from an acute illness or acute exacerbation of a chronic disease within 3 days before the first vaccination; * Positive urine pregnancy test result or lactation in female participants of childbearing age, or pregnancy planning for female participants of childbearing age, male participants and their female sexual partners from the start of the trial until 6 months after the completion of the full vaccination course; * History of severe allergies requiring medical intervention or severe adverse reactions to vaccines (such as severe urticaria, anaphylactic shock, allergic laryngeal edema, allergic purpura, local allergic necrotizing reaction (Arthus reaction), angioedema, etc.), or allergy to any component of the investigational vaccine, such as human albumin, dextran 40, sucrose, glycine, disodium hydrogen phosphate, potassium dihydrogen phosphate; * Known or suspected malignant tumor, autoimmune …